# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pierre Le Moyne d'Iberville (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET014-SYN
- Date: 2026-02-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marguerite Delacroix-Boateng, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for new patient visit for recurrent fevers with chills after naval service in malaria-endemic areas, and an expected tropical deployment: history, examination, malaria testing, quantitative G6PD, and an infectious diseases (travel medicine) referral. **S**

## Objective

Hemoglobin: 13 g/dL (low); White cell count: 5.6 10*3/uL; Platelets: 141 10*3/uL (low); Sodium: 139 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 0.98 mg/dL; Glucose: 92 mg/dL; ALT: 34 U/L; AST: 29 U/L; Total bilirubin: 1.1 mg/dL; G6PD activity: 11.8 U/g{Hb}; eGFR: 98 mL/min/1.73 m². All results are synthetic.

BP 124/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 68.4 kg; BMI 22.3 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requested; Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccines. Strengths and supports remain part of the care plan. **S**

## Medication changes

- No medication changes. **S**

## Plan

- Infectious diseases (travel medicine) consultation in two weeks to establish the cause of the recurrent fevers, advise on antirelapse treatment, and plan pre-travel care for the deployment. Guideline: Treatment of Uncomplicated Malaria (clinical guidance) (2026); The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006) **S**
- Malaria testing between attacks: thick and thin blood smears, rapid antigen test, and Plasmodium species PCR sent to the reference laboratory; quantitative G6PD activity before any primaquine; blood count, kidney and liver tests. Guideline: Treatment of Uncomplicated Malaria (clinical guidance) (2026) **S**
- Fever action plan: a blood smear the same day for any fever, at home, at sea or after travel; carry a card stating his malaria history. Guideline: Treatment of Uncomplicated Malaria (clinical guidance) (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026) **S**
